Conq Conqueri ering g Up Uppe per r Limb Limb Para Paraly - - PowerPoint PPT Presentation

Conq Conqueri ering g Up Uppe per r Limb Limb Para Paraly lysi sis s with with Wea Wearab rable e Me Medic dical al Robo Roboti tics cs

Q2 Q2 20 2018 18 Earn Earnings Presenta ings Presentation tion Aug ugust ust 7, , 20 2018 Paul Paul R. . Gudo Gudonis nis, , Chairman hairman and and C CEO EO Ralph alph Go Goldw ldwasser, asser, CFO FO

1

Legal Disclaimer

This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company’s management and its knowledge of the relevant

• market. The Company has tried, where possible, to identify such information and statements by using words such as

“anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and

• ther factors. These risks and uncertainties include, among others, risks related to the Company’s liquidity and financial

position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in Myomo's Form S-1 Registration Statement filed with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

2

Scaling Up to Meet Large Unmet Need

Addressable Market = Est. 25% of US: 3,000,000 Prevalence + 350,000 New Cases per Yr. + Worldwide Market Upper Extremity Paralysis

3

Investing in Revenue Growth with New Capital

June 2017

U.S Sales & Marketing Product Development Clinical Studies & Reimbursement International Expansion

• Dec. 2017

Follow-on Offering = $11.5M IPO + Private Placement = $7.9M 4 Programs for Revenue Growth:

4

Resulting in Record Revenue Q2 2018

5 100,000 200,000 300,000 400,000 500,000 600,000 700,000 1Q 2Q 3Q 4Q 2016 2017 2018

+45% +106%

#1 Expanded US Distribution and Direct-to-Patient Marketing is Generating Demand

6

Step 1 Open New Regions Hire Business Development Manager and Clinical Support Step 2 Expand Distribution Channel Recruit & Train O&P Clinics Step 3 Launch Digital Marketing Campaign Host Patient Screening Days

Step 1: Opening New Sales Regions

7

Field Sales and Clinical Support

Step 2: Growing Roster of O&P Clinic Locations

8

Step 3: Launching Local Digital Marketing Activity

9

Screening Day Schedule

10

Growing # of Patient Screening Days Patient Pipeline

11 10 20 30 40 50 60 70 80 Q1 Q2 Q3

Screening Days

#2: Product Development to Expand Market

ADULTS (MyoPro2 JUNE 2017) ADOLESCENTS (JUNE 2018) PEDIATRICS (TBD)

12

Adolescent Launch

13

• Press Release
• Website Home Page and Landing Page
• Patient Champion Video
• Case Study
• Pilot Programs at
• Easterseals Chicago
• Shriner’s Chicago
• UCP Cleveland

Medicare Code Application – Status

Dec 2017 May 2018 Fall 2018 Q1 2019 (Est) File HCPCS Preliminary Coverage Policy New Code, Code Decision to Determination; Policy, and Application Establish New Allowable Fee With CMS Code Reimbursement Go Live Amount Issued

14

Note: There is no guarantee that CMS will follow through with code for MyoPro, coverage policy, or reimbursement amount

#4: Entering International Markets

15

Building European Distribution Network

16

• Attended OT World Conference

in May 2018

• Ottobock Has Fit Initial Patients

in Germany

• Ottobock Will Be Exclusive

MyoPro Distributor in Germany

European Target Countries

• Established Myomo Business

Development Office in Europe

• Led by John Frijters, former Ottobock

and ReWalk exec in Europe

• Recruiting Distributors in Selected

Countries in Europe

17

New Hire: Micah Mitchell, Chief Commercial Officer

18

• Mission: Scale Revenue!
• “Front end of the business”: Field sales, Clinical

Support, Channels, Marketing, Reimbursement, and Order Administration

• 20 years of experience in rapidly scaling

companies in custom DME mobility solutions:

• Invacare, Alliance Seating and Mobility,

Apria Healthcare Group

• Sales management, Payer contracts,

Direct-to-consumer marketing

Revenue and Gross Margin - QTD

19

QUARTER ENDED JUNE 30, REVENUE 2018 2017 $ Change % Change Product Revenue $ 627,887 $ 242,230 $ 385,657 159% Grant Revenue 4,482 64,453 (59,971) (93)% TOTAL $ 632,369 $ 306,683 $ 325,686 106% GROSS MARGIN $ 431,923 $ 208,042 68% 68%

Revenue And Gross Margin - YTD

20

SIX MONTHS ENDED JUNE 30, REVENUE 2018 2017 $ Change % Change Product Revenue $ 936,548 $ 440,023 $ 496,525 113% Grant Revenue 9,000 82,891 (73,891) (89)% TOTAL $ 945,548 522,914 $ 422,634 81% GROSS MARGIN $ 637,022 $ 345,704 67% 66%

Gross Margin and Operating Expenses

21

QUARTER ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2018 2017 $ Change 2018 2017 $ Change Gross Margin $ 431,923 $ 208,042 $ 223,881 $ 637,022 $ 345,704 $ 291,318 Research and Development 486,982 708,622 (221,640) 859,341 1,065,507 (206,166) Selling, general and administrative 2,627,005 1,432,862 1,194,143 4,862,642 2,577,328 2,285,314 3,113,987 2,141,484 972,503 5,721,983 3,642,835 2,079,148 Loss from operations $(2,682,064) $(1,933,442) $ (748,622) $ (5,084,961) $ (3,297,131) $ (1,787,830)

Financial Position

22

• Jun. 30, 2018
• Dec. 31, 2017

Cash $11.7M $12.9M Total Assets $13.1M $13.9M Debt $0.0M $0.0M Total Liabilities $1.6M $1.5M Stockholders' Equity $11.5M $12.4M Total Liabilities and Stockholders' Equity $13.1M $13.9M

Investor Summary: Catalysts for Growth

23

MYO Current Base #1: Increased US Distribution & Direct-to-Patient Marketing = More Demand # 2: New Product Development = More Target Patients #3: Medicare Reimbursement Potential = Greater Patient Access #4: International Markets = More Population